A personalised mRNA cancer vaccine, given alongside the immunotherapy drug pembrolizumab (Keytruda), cut the risk of melanoma coming back or causing death by 42% compared with pembrolizumab alone in a large phase 3 trial. The full results of the INTerpath-001 trial, run by Merck and Moderna, were published in the New England Journal of Medicine on 11 November 2026.
This is the first positive phase 3 result for an mRNA-based cancer treatment. It’s a big moment for cancer research, but it isn’t a vaccine you can ask for at your next appointment, and it doesn’t prevent melanoma in healthy people. Here’s what the study found, who it might help, and what’s still unknown.
What happened
The treatment is called intismeran autogene (also known as V940 or mRNA-4157). The topline result was announced in August 2026. Detailed data were presented at the European Society for Medical Oncology (ESMO) Congress in October, and the peer-reviewed paper appeared in NEJM on 11 November. The study’s principal investigator is Professor Georgina Long of Melanoma Institute Australia.
The trial enrolled 1,137 adults whose melanoma had been completely removed by surgery but who had a high chance of it returning (stage IIB to stage IV). They were randomly assigned, in a 2:1 ratio, to:
- intismeran injections every 3 weeks (up to 9 doses) plus pembrolizumab every 6 weeks (up to 9 cycles), or
- placebo plus pembrolizumab on the same schedule.
Treatment lasted about a year.
The key numbers
| Result at 2 years | Vaccine + pembrolizumab | Pembrolizumab alone |
|---|---|---|
| Free of recurrence (recurrence-free survival) | 82.2% | 70.0% |
| Free of spread to distant organs (distant metastasis-free survival) | 88.5% | 80.2% |
| Serious (grade 3 to 5) treatment-related side effects | 14.2% | 13.4% |
| Fever (any grade) | 52.2% | 8.2% |
| Injection site pain | 51.0% | 9.5% |
Figures as reported by Targeted Oncology’s coverage of the ESMO presentation and Moderna’s results summary.
The overall hazard ratio for recurrence or death was 0.58, which is where the “42% lower risk” comes from. For distant spread, the hazard ratio was 0.62, a 38% lower risk.
One detail stood out. In the first six months, the two groups did about the same (hazard ratio 0.99). The benefit showed up after that, with a hazard ratio of 0.42 from six months on. That fits with how the vaccine works: it takes time to train the immune system.
How a “personalised” cancer vaccine works
This isn’t a vaccine in the usual sense of preventing an infection. It’s a treatment built for one person’s tumour.
- After surgery, a sample of the tumour and a normal blood sample are sequenced.
- Computers compare them to find mutations that exist only in the cancer cells.
- The most promising targets (up to 34 “neoantigens”) are chosen.
- A custom mRNA molecule is made that tells the body’s cells to briefly produce those cancer-specific fragments.
- The immune system learns to recognise them, while pembrolizumab takes the brakes off immune cells so they can attack any remaining cancer cells.
Moderna says the vaccine was successfully made for more than 99% of people randomised to receive it, which matters because every dose is unique.
What changes for you
For now, nothing changes in day-to-day care. Intismeran isn’t approved anywhere. Merck and Moderna say they’re talking with regulators about filing, but no submission to the US FDA, the UK’s MHRA or the European Medicines Agency has been publicly announced. Moderna’s own forward-looking statements mention possible approval in 2027, but that isn’t guaranteed.
If approval does come, it would most likely be for adults with high-risk melanoma that has been fully removed, in combination with pembrolizumab, which is the setting tested.
Who could benefit
- Adults with stage IIB to IV melanoma removed by surgery. That’s the group studied. They hadn’t had previous drug treatment for melanoma.
- Not people without cancer. It’s not a preventive jab against skin cancer.
- Not yet other cancers. Trials are under way in lung, bladder and kidney cancer, but results there aren’t in.
If you or a family member have had melanoma removed and are on, or being considered for, pembrolizumab, it’s reasonable to ask your oncologist whether any trials of personalised cancer vaccines are recruiting near you.
What’s still unclear
- Does it help people live longer? Overall survival data aren’t mature yet. Companies report a “favourable trend”, but that isn’t a result.
- Cost and access. A treatment made individually for each patient is likely to be expensive and need specialist labs. No price has been announced.
- Time to make it. Each batch is custom. How quickly it can be produced in routine care, outside a trial, matters.
- Who benefits most. Subgroup results by stage and tumour type will shape who gets it first.
What you can do now about melanoma
The best protection is still catching melanoma early and reducing UV damage. The NHS lists these warning signs in a mole or skin mark:
| Check | What to look for |
|---|---|
| Asymmetry | Two halves that don’t match |
| Border | Uneven, ragged or blurred edges |
| Colour | Two or more colours |
| Diameter | Often wider than 6 mm, though early melanomas can be smaller |
| Evolving | Changing size, shape or colour; itching, bleeding or crusting |
When to see a doctor
Book an appointment with your GP or doctor if you notice:
- a mole that has changed in size, shape or colour
- a mole that’s painful, itchy, inflamed, bleeding or crusty
- a new or unusual mark that hasn’t gone after a few weeks, including on the palms or soles
- a dark area under a nail that wasn’t caused by an injury
Melanoma is one of several cancers worth knowing the early signs of. Our guide to cancers rising in younger adults covers others. If you’re weighing sun protection against getting enough vitamin D in winter, see our piece on vitamin D deficiency and safe sun. And if you want a feel for how to read health headlines about new research, our breakdown of the ultra-processed food and bowel cancer study walks through one.
Frequently asked questions
Is the mRNA melanoma vaccine available now?
No. It’s still experimental. It can only be received through a clinical trial until a regulator approves it.
Is this the same technology as COVID-19 mRNA vaccines?
It uses the same basic idea, mRNA instructions that tell cells to make a protein fragment. But instead of a virus protein, it encodes fragments unique to a person’s own tumour, and it’s used as a treatment after surgery.
Does it cure melanoma?
No one should describe it that way. It lowered the chance of melanoma returning over two years, but some people in both groups still relapsed, and longer-term survival data aren’t in yet.
What were the main side effects?
Fever, injection site pain and tiredness were the most common. Serious treatment-related side effects were similar between groups (14.2% vs 13.4%).
Could it work for other cancers?
That’s being tested. Merck and Moderna are running trials in non-small cell lung cancer, bladder cancer and kidney cancer, with no phase 3 results there yet.
This article is for general information and is not a substitute for advice from a doctor. If you have symptoms or a health condition, please consult a qualified healthcare professional.

